Sunovion to acquire Elevation Pharma

Thursday, August 30, 2012 01:42 PM

Sunovion Pharmaceuticals, a Marlborough, Mass.-based pharmaceutical company focused on the central nervous system and respiratory disease, has agreed to acquire San Diego-based Elevation Pharmaceuticals, which specializes in the development of new aerosol therapies for patients with respiratory diseases.

The acquisition includes Elevation Pharmaceuticals' EP-101 product, an inhalation solution of a long-acting muscarinic antagonist (LAMA) bronchodilator that is in phase IIb clinical trials for the treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Sunovion will make an upfront payment of $100 million to the shareholders of Elevation on closing of the acquisition of its shares, and thereafter it will make development milestone payments for EP-101 up to $90 million. Furthermore, after the regulatory approval, Sunovion will also make commercial milestone payments up to $210 million. Subsequent milestone payments up to $30 million could occur contingent upon the successive development of additional new programs.

"Nebulized medicine is an important treatment option for older and sicker patients—the fastest growing segment within COPD," said Bill Gerhart, founder and CEO of Elevation Pharmaceuticals. "Sunovion is the ideal sponsor to realize our original vision to significantly elevate the standard of care for this underserved patient population."

The boards of both Sunovion and Elevation have approved the transaction. The acquisition is subject to customary closing conditions.

Share:          
CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs